Showing 3861-3870 of 9150 results for "".
- Pierre Fabre Obtains FDA Approval to Market Hemangeol for the Treatment of Infantile Hemangiomahttps://practicaldermatology.com/news/20140319-pierre_fabre_obtains_fda_approval_to_market_hemangeol_for_the_treatment_of_infantile_hemangioma/2459311/Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for “proliferating infantile hemangioma requiring s
- Cutera Announces Enhancements to its Sales and Marketing Organizationhttps://practicaldermatology.com/news/20131127-cutera_announces_enhancements_to_its_sales_and_marketing_organization/2459400/Cutera, Inc. recently announced enhancements to its sales and marketing organization. Kevin Connors, President and CEO of Cutera, stated, "We are pleased with our portfolio of product offerings and ex
- Antares Pharma Enters into Promotion and Marketing Agreement with LEO Pharma for Otrexuphttps://practicaldermatology.com/news/20131118-antares_pharma_enters_into_promotion_and_marketing_agreement_with_leo_pharma_for_otrexup/2459413/Antares Pharma, Inc. announced an exclusive agreement with LEO Pharma for the promotion and marketing of Otrexup (methotrexate) to dermatologists for symptomatic c
- North American Facial Injectable Market to Hit $1.7 Billion by 2017https://practicaldermatology.com/news/20121228-north_american_facial_injectable_market_to_hit_17_billion_by_2017/2459652/According to Millennium Research Group, the North American facial injectables market, comprising botulinum toxin and dermal fillers sold in the US and Canada, will continue to show strong growth for the next five years, reaching a total value of more
- Amgen, Pfizer Will No Longer Co-Market Enbrelhttps://practicaldermatology.com/news/20120419-amgen_pfizer_will_no_longer_co-market_enbrel/2459819/Amgen and Pfizer will end co-promotion of Enbrel (etanercept) in North America this summer, the companies tell the Wall Street Journal. Amgen will assume full marketing responsibilities in the US, effective July 23.
- NYC PrideFest: Galderma Aesthetics to Participatehttps://practicaldermatology.com/news/nyc-pridefest-galderma-aesthetics-to-participate/2461249/Galderma is participating in New York City's official LGBTQIA+ Pride (NYC Pride) event. This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a u
- Emerging Treatments for CLE Highlighted at Fall Clinicalhttps://practicaldermatology.com/news/emerging-treatments-for-cle-highlighted-at-fall-clinical/2484091/Cutaneous lupus erythematosus (CLE) patients often face long treatment timelines, drug toxicity, and misdiagnoses, but recent advances in mechanism-based agents mark a significant step forward, Lauren Graham, MD, PhD, and Alisa Femia, MD, said during a presentation at the 2025 Fall Clinical Derma
- Bill Collection Made Tougher by Recent Changes in Credit Reportinghttps://practicaldermatology.com/news/Bill-Collection-Made-Tougher-Recent-Changes-Credit-Reporting/2471259/Americans owe $220 billion in medical debt,1 and the most effective method for collecting money could soon cease to be an option. Mark Nestor, MD, PhD, highlighted this issue during a presentation at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “Ba
- Dr. Lebwohl: Don't Delay GPP Treatment for TB Testing or Skin Biopsyhttps://practicaldermatology.com/news/Dr-Lebwohl-Dont-Delay-GPP-Treatment-TB-Testing-Skin-Biopsy/2471222/Generalized pustular psoriasis (GPP) treatment should not be delayed while waiting for a tuberculosis screening, according to Mark Lebwohl, MD. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Lebwohl recommended initiating spesolimab therapy immediately
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como